<DOC>
	<DOCNO>NCT01475552</DOCNO>
	<brief_summary>The researcher aim investigate effect point-of-care platelet function assay periprocedural cardiac enzyme elevation patient diabetes mellitus . All patient suppose undergo coronary angiography load clopidogrel ( 300mg ) aspirin ( 300mg ) D-1 . If patient determine implant coronary stent diagnostic coronary angiography , platelet function assay Verifynow-ADP ( Accumetrics ) . If patient &gt; 270 unit assay , randomize abciximab control group . After successful stent implantation , cardiac enzyme ( CK-MB , Troponin-I ) follow 8hr , 16hr 24hr . Clinical outcome include bleed complication assess 1 month .</brief_summary>
	<brief_title>Tailored Antiplatelet Therapy During Percutaneous Coronary Intervention Patients With Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Abciximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoglobulin Fab Fragments</mesh_term>
	<criteria>Patients determine implant drugeluting coronary stent Diabetes mellitus ( type 1 2 ) Age &lt; 18 year &gt; 80years Patients acute myocardial infarction Patients history cerebral hemorrhage ever ischemic infarction within 2 year Patients history major surgery ( abdominal , thoracic , intraocular ) within 6 month Patients allergy antiplatelet medication ( aspirin , clopidogrel , abciximab ) Patients anticoagulation therapy Serum creatinine &gt; 2.0mg/dl ALT/AST &gt; 3 time upper normal limit ( 120 U/L )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>platelet reactivity</keyword>
	<keyword>platelet function assay</keyword>
	<keyword>abciximab</keyword>
	<keyword>tailor therapy</keyword>
</DOC>